Phase 1b/2a Safety and Tolerability of SYN-004 in Allo-HCT Subjects

Condition:   121121000119106, Reduction of the Incidence and/or Severity of Acute Graft-versus-host Reaction Following Bone Marrow Transplant (Disorder) Intervention:   Biological: SYN-004, Ribaxamase or Placebo Sponsors:   Synthetic Biologics Inc.;   Washington University School of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials